Patient Characteristics and Screening
REMISSION, METASTATIC DISEASE, -20
Seventy patients from four European centers were screened between November 2010 and November 2017; two patients failed screening, and 68 patients were finally enrolled and analyzed. Median age at study entry was 6.5 years (range, 3-20); all but four patients (94.1%) had metastatic disease at relapse. Median observation time from initiation of immunotherapy was 7.8 years.Most patients (67/68; 98.5%) received chemotherapy for relapse, 39 (57.4%) had surgery, 26 (38.2%) received radiotherapy, and 43 (63.2%) received Patient/Disease Characteristics and OutcomesMost patients improved (48/68; 70.6%) or maintained (18/68; 26.5%) their remission status after haplo-SCT (Table 